Verified July 2026 · Cited to primary sources
The peptides behind the "wolverine stack" and injury-recovery culture, graded by human evidence and legal status. This is the most-hyped category, and the one where the evidence is thinnest.
Strongest human evidence in this category
The famous recovery peptides (BPC-157, TB-500, KPV) are all Grade D (animal studies only) and under FDA review (July 2026 PCAC). Sermorelin (Grade B) is the only option here with real human data and a legal route. Bottom line: the recovery claims outrun the human evidence.
How we ranked these
We don't rank by popularity or by what we can sell you. Every peptide below is ordered by the same fixed rubric, and affiliate availability never moves a grade.
A historical FDA survey of compounded drugs found 31% failed standard potency testing. What is actually in the vial is a separate question from whether the compound works, and a rubric like this exists to keep the two apart. See the full A to F methodology →
Stimulates natural pituitary growth-hormone release as the shortest active GHRH(1-29) fragment. The "gentler," physiologic GH-axis peptide.
Sermorelin is legally compoundable (503A) thanks to its prior FDA approval as Geref. Human evidence is Grade B: real historical trial data. It is the best-evidenced GH-axis peptide with a legal supervised route today.
See the evidence →The main job of thymosin beta-4 is to bind and sequester G-actin, the building-block protein of the cell skeleton. By managing the actin pool it drives cell migration, which is central to wound healing. It also promotes new blood vessel growth (angiogenesis), tamps down inflammatory signaling, and can reduce cell death after injury. TB-500 is a widely sold fragment marketed as a related actin-binding peptide. These mechanisms explain the interest in healing, cardiac repair, and the cornea.
Two different stories share one molecule. As an eye drop (RGN-259) it has legitimate positive human trials and grades a B. As the injectable TB-500 that the recovery crowd actually buys, human efficacy data is basically absent, and you are extrapolating from animal healing studies. It is not FDA-approved in any form. If you are drawn to it for tendon or muscle recovery, be clear-eyed that you are self-experimenting with an unapproved, WADA-banned peptide whose human evidence lives in ophthalmology, not sports medicine.
See the evidence →Non-peptide agonist of the ghrelin receptor (GHS-R1a) that mimics ghrelin to drive sustained, roughly physiological increases in growth hormone and IGF-1. Because it is orally bioavailable and long-acting, one daily dose keeps GH/IGF-1 elevated, unlike the injectable peptide GHRPs. That same sustained GH/IGF-1 elevation is what drives its main downside: reduced insulin sensitivity and higher fasting glucose.
The most-studied and only orally-active option in this group, with genuine 2-year human RCT data behind it, which is why it grades C and not D. But the same trial that proves it works also shows the catch: modest lean-mass gain, no functional benefit, and worse insulin sensitivity. Not FDA-approved, research-only, and a poor idea for anyone with blood-sugar concerns.
See the evidence →Cibinetide is a short peptide based on a region of erythropoietin (EPO). Crucially, it does NOT stimulate red blood cell production the way EPO does. Instead it activates the innate repair receptor, a heteroreceptor complex, which switches on anti-inflammatory and tissue-protective, tissue-regenerating signaling. In the neuropathy studies this shows up as actual regrowth of small nerve fibers. That separation of tissue repair from the blood-thickening effects of EPO is the whole point of the molecule.
The most scientifically elegant peptide in this group: an EPO fragment engineered to keep the tissue-repair upside and drop the blood-clotting downside, with small human trials actually showing small nerve fibers regrowing. That is genuinely novel. But novel is not the same as proven, and the whole human record is a handful of small trials in one rare disease. Grade C. Worth watching for its neuropathy potential, not something to buy as a research chemical and inject based on a couple of pilot studies.
See the evidence →Elamipretide is a small cell-permeable tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and binds cardiolipin. By stabilizing cardiolipin and the associated respiratory-chain supercomplexes, it is proposed to improve electron transport efficiency, reduce reactive oxygen species, and restore ATP production in mitochondria that are dysfunctional. Because mitochondrial dysfunction sits underneath many age-related and rare diseases, it has been tested across mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
The most legitimate science on this list, and still not a green light. Elamipretide is a real drug candidate with a plausible mitochondrial mechanism and clean tolerability, but its flagship mitochondrial-myopathy Phase 3 missed its endpoints. The dry-AMD program is the one to watch. Until a Phase 3 reads out positive and it earns approval, treat grey-market SS-31 as an unproven, unapproved injectable and keep expectations low.
See the evidence →Promotes angiogenesis and tissue repair by upregulating growth-factor/VEGF and nitric-oxide pathways. Marketed as a "healing" peptide for gut, tendon and muscle injury, but that use is experimental.
BPC-157 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for ulcerative colitis, overriding the FDA's own scientists, but that is a recommendation only and the FDA has not decided. Human evidence stays Grade D: animal studies only. If you pursue it, wait for the FDA's ruling and use a licensed provider, never gray-market vials.
See the evidence →Regulates actin and promotes cell migration, angiogenesis and wound healing. Marketed for soft-tissue and tendon recovery.
TB-500 is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: the fragment sold to consumers has animal data only. The full-length Tβ4 human trials are a different molecule.
See the evidence →Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.
KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials.
See the evidence →MGF is the C-terminal E-domain of the IGF-1Ec splice variant, produced locally in skeletal muscle in response to mechanical overload or damage. The proposed mechanism is autocrine/paracrine activation of muscle satellite cells (the resident stem cells that repair and enlarge fibers), acting through a receptor distinct from the classic IGF-1 receptor. In practice the receptor and downstream signaling remain poorly characterized, and whether the synthetic peptide reproduces the biology of the natural splice event is unresolved.
Skip it. The idea (a local muscle-repair growth factor you can inject) is attractive, but the honest read of the literature is preclinical at best and negative in the one rigorous cell study. There is no human evidence it builds muscle, it is banned in sport, and injecting an unverified growth factor is not a low-risk bet.
See the evidence →PEG-MGF is the MGF (IGF-1Ec E-domain) peptide conjugated to polyethylene glycol. Native MGF has a very short systemic half-life (minutes); PEGylation slows clearance and is meant to give the peptide time to reach tissue and act on satellite cells. The proposed downstream biology is identical to MGF: satellite cell activation, proliferation, and fusion to support fiber repair and hypertrophy. Whether extending the half-life of a peptide that may not be active in the first place produces a real anabolic effect is exactly the open question.
Skip it. PEG-MGF is a chemically reasonable attempt to fix MGF's short half-life, but fixing the delivery of a compound with no proven human effect does not create a proven human effect. Animal data only, banned in sport, unverified injectable. Not worth the risk.
See the evidence →| Peptide | Evidence | Legal & safety | Typical cost | Verdict | |
|---|---|---|---|---|---|
| Sermorelin The "gentler," formerly-FDA-approved GH-axis peptide. It's the best-evidenced option you can still legally get through a compounding pharmacy. | Grade B | See evidenceSee the evidence for Sermorelin | |||
| Thymosin Beta-4 A 43-amino-acid tissue-repair peptide. It has real human eye-drop trials (RGN-259) but is not FDA-approved, and the injectable bodybuilding version (TB-500) has essentially no human data. | Grade B | See evidenceSee the evidence for Thymosin Beta-4 | |||
| MK-677 (Ibutamoren) The odd one out: MK-677 is not a peptide, it is an orally-active small-molecule ghrelin mimetic, which is why people take it as a daily capsule instead of an injection. It has the best human evidence in this group by far, including a 2-year randomized trial, but that trial is also the cautionary tale: it raised lean mass a little while measurably worsening insulin sensitivity and blood sugar. | Grade C | See evidenceSee the evidence for MK-677 (Ibutamoren) | |||
| ARA-290 (Cibinetide) An 11-amino-acid fragment derived from erythropoietin that triggers tissue repair without boosting red blood cells. It has small positive human nerve-regeneration trials, which makes it an honest C. | Grade C | See evidenceSee the evidence for ARA-290 (Cibinetide) | |||
| SS-31 (Elamipretide) The most seriously studied peptide on this list, run through real Phase 3 trials. Its flagship mitochondrial-myopathy trial missed its primary endpoints, but its dry-AMD program is still advancing, so the honest verdict is mixed, not settled. | Grade C | See evidenceSee the evidence for SS-31 (Elamipretide) | |||
| BPC-157 The most-hyped, least-human-proven "healing" peptide. Extensive rodent data, zero published human trials. | Grade D | See evidenceSee the evidence for BPC-157 | |||
| TB-500 The other half of the "wolverine stack." Soft-tissue recovery claims, but only animal data for the fragment actually sold. | Grade D | See evidenceSee the evidence for TB-500 | |||
| KPV An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans. | Grade D | See evidenceSee the evidence for KPV | |||
| MGF (Mechano Growth Factor) A short splice variant of IGF-1 that muscle makes locally after mechanical stress. The theory is great, the human data barely exists, and the one well-run cell study said it did nothing. | Grade D | See evidenceSee the evidence for MGF (Mechano Growth Factor) | |||
| PEG-MGF (Pegylated Mechano Growth Factor) MGF with a polyethylene glycol tail bolted on to make it last longer in the blood. Longer half-life, same problem: the evidence is animal-only and no human trial has shown it does anything. | Grade D | See evidenceSee the evidence for PEG-MGF (Pegylated Mechano Growth Factor) |
Reading this table: Evidence is the A to F human-proof grade; Legal status and Safety are separate factual badges; Verdict is our honest one-line take. Affiliate availability never changes a grade. Full methodology.
FAQ
The famous recovery peptides (BPC-157, TB-500, and KPV) are all Grade D (animal studies only) and under FDA review ahead of the July 2026 PCAC vote. Sermorelin (Grade B) is the only option here with real human data and a legal compounding route. Bottom line: the recovery claims outrun the evidence.
No. Both BPC-157 and TB-500 are Grade D: animal studies only, with no published human efficacy trials. The stack is a community protocol, not something validated in humans, and we don't provide dosing for it.
There is no legal supervised US route to BPC-157 or TB-500 today. Both were removed from the 503A Category 2 list in April 2026 and are on the July 23, 2026 PCAC docket. Vials sold "for research use only" are a gray-market fig-leaf, not a legal route.
Read the evidence
Before you buy anything
Other goals
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.